Fred Hutch's Value in Cancer Care conference, held November 6, focused on patient and provider burnout; the growing data ...

In this episode of the Oncology Insights Podcast, Dr. Petros Grivas welcomes Dr. Christina Rodriguez to discuss her journey ...

GVHD can range from mild and temporary to life-threatening and chronic — but the deadly, debilitating cases are rare now. As ...

Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...

On Oct. 9, 2025, Fred Hutch Cancer Center employees with decades of service were honored at a luncheon celebrating their ...

Today, Fred Hutch announced that in 2025 the Obliteride community raised $9.2 million for groundbreaking research. This amount brings Obliteride’s cumulative fundraising total to more than $67 million ...

A new $5.2 million grant from the Washington Research Foundation will help develop a new clinical trials program between Fred ...

New Fred Hutch Cancer Center viral immunologist Dr. Paul Thomas is working to turn the "incredible potential" of the immune system into real-life diagnostic and therapeutic applications. He studies ...

AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with initial funding SEATTLE – Oct. 2, 2024 – Four National Cancer ...

A study published in Nature finds that some cancer patients can make their “own companion drug,” suggesting a potential template for future treatments SEATTLE — July 23, 2025 — A landmark study has ...

Stuart and Molly Sloan add to their 2022 transformational gift to boost their impact on research and care SEATTLE – July 22, 2025 – A Fred Hutch Cancer Center outpatient complex serving more than ...

Study aims to understand the effectiveness and use of multi-cancer detection blood tests SEATTLE – July 15, 2025 – Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national ...